Clinical Trial

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Study acronym: CERT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04 -> 2027-04 2026-05-12
minor Completion pushed: 2026-07 -> 2027-07 2026-05-12
Trial Details
NCT Number NCT04886284
Lead Sponsor Todd C. Lee MD MPH FIDSA
Conditions Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
Enrollment 60 participants
Start Date 2024-05-20
Primary Completion 2027-04 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-27